The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drugmaker that had primarily grown by acquisitions and drug-price hikes in recent years, galloped higher by 43% in November, according to data from S&P Global Market Intelligence. While the stock is still more than 90% off its all-time high, the monthly return was one of the best shareholders have seen in recent years -- and they owe it all to the company's encouraging third-quarter operating results.
For the quarter, Valeant reported $2.22 billion in sales, down about 10% from the previous year, as well as $367 million in adjusted net income, down from $510 million in the prior-year period. Scratching the surface, these headline figures don't look very appetizing. However, the underlying details were what excited investors.
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Aktie
Aktuell gibt es mit 5 Buy-Einschätzungen und 0 Sell-Einschätzungen ein positives Sentiment für die Bausch Health Companies Inc. Aktie.
Die Community prognostiziert für Bausch Health Companies Inc. ein Kursziel von 16 €, was eine Steigerung von mehr als 100% gegenüber dem aktuellen Kurs von 5.52 € bedeutet.
